CATTANEO, DANIELE
CATTANEO, DANIELE
Dipartimento di Oncologia ed Emato-Oncologia
Characterization of a Newly Discovered Non‐Coding Variant in the EPO Gene Identified in Two Unrelated Italian Pedigrees With Erythrocytosis
2026 B. Mora, V. Bellani, D. Pietra, E. Tagliaferri, D. Cattaneo, O. Borsani, A. Iurlo, E. Fermo, P. Bianchi, E. Rumi, F. Passamonti
Thermo‐Chemically Modified Silk Scaffolds Reveal Niche‐Driven Regulation of Hematopoiesis and Fibrosis
2026 C.A. Di Buduo, C.P. Miguel, G. Della Rosa, V. Abbonante, S. Diprima, D. Tosi, M. Filibian, D. Cattaneo, J.K. Sahoo, N. Tirelli, A. Iurlo, U. Gianelli, D.L. Kaplan, A. Balduini
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis
2026 B. Mora, M. Franchi, L. Margotto, O. Leoni, D. D'Ippoliti, E. Carloni, I. Cozzi, E. Santelli, F. Gemmi, C. Szasz, M. Maffioli, C. Gurnari, E. Attardi, D. Cattaneo, M. Bortolotti, N.S. Fracchiolla, A. Iurlo, G. Corrao, M.G. Della Porta, A.M. Vannucchi, M.T. Voso, P. Guglielmelli, F. Passamonti
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study
2026 A. Iurlo, D. Cattaneo, C. Fava, F. Castagnetti, M. Bonifacio, M. D'Adda, M.C. Miggiano, I. Capodanno, C. Elena, L. Levato, A.R. Scortechini, F. Lunghi, M. Caramella, N. Orofino, M. Maffioli, V. Bellani, V. Bonuomo, S. Grano, G. Cotilli, E. Scalzulli, M. Dalmazzo, S.L. Crescenzi, L. Luciano, B. Martino, T. Intermesoli, D. Rapezzi, G. Binotto, M. Tiribelli, D. Consonni, F. Pane, G. Saglio, C. Gambacorti‐passerini, M. Breccia, G. Rosti
Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis
2026 F. Palandri, G. Caocci, E. Abruzzese, M. Tiribelli, E. Morsia, M. Farina, G. Benevolo, E. Beggiato, B. Martino, N. Pugliese, A. Tieghi, M. Crugnola, G. Binotto, F. Cavazzini, A. Iurlo, A. Isidori, A. Dedola, E. Scalzulli, A. Duminuco, D. Cattaneo, R.M. Lemoli, C. Bosi, D. Cilloni, M. Bocchia, F. Pane, C. Sartor, F.H. Heidel, M. Breccia, F. Branzanti, G.A. Palumbo, M. Bonifacio, E.M. Elli
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design
2025 V. De Stefano, F. Passamonti, F. Palandri, F. Ramundo, E. Rossi, S. Betti, L. Fagiolo, P. Guglielmelli, D.P. Abagnale, N. Pugliese, D. Cattaneo, A. Iurlo, F. Branzanti, A. Dedola, H. Catellani, A. Tieghi, M. Basso, E. Calistri, E.M. Elli, E. Masselli, E. Morsia, G. Benevolo, M. Breccia, V. De Fazio, M. Di Perna, M. Marchetti, M. Santoro, A. Tafuri, C. Castiglioni, C. Rotella, S. Siragusa, A.M. Vannucchi, N. Null
Granuloma annulare-like pseudohistiocytosis: a specific manifestation of ETV6::SYK-rearranged myeloid neoplasm with eosinophilia
2025 G.A. Croci, D. Cattaneo, S. Tabano, I. Catusi, M. Zappa, C.A. Maronese, N. Bolli, A.V. Marzano, A. Iurlo
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study
2025 A. Sicuranza, P. Pacelli, A. Santoni, E. Abruzzese, D. Cattaneo, A. Iurlo, L. Luciano, S. Galimberti, V. Giai, O. Mulas, G. Caocci, F. Sorà, I. Capodanno, M. Crugnola, A. Gozzini, S. Russo, M. Annunziata, C. Fozza, A. Cartocci, S. Fredducci, E. Pacini, A.M. Liberati, M. Defina, E. Bestoso, C. Marzano, D. Tocci, T. Miracapillo, C. Turriziani, K. Peccia, D. Raspadori, M. Bocchia
Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy
2025 A. Iurlo, C. Bucelli, T. Intermesoli, C. Elena, M. D'Adda, E. Agostani, C. Fiamenghi, M. Maffioli, N. Orofino, F. Lunghi, A. Gardellini, M.C. Carraro, A. Inzoli, F. Gigli, R. Palazzolo, V. Bertolli, D. Cattaneo, E.M. Pungolino, C. Gambacorti-Passerini
Reply to: Association between nilotinib-induced hyperbilirubinemia and UGT1A1 polymorphisms in a chronic myeloid leukemia patient
2025 D. Cattaneo, A. Iurlo
Circulating Levels of PF4/CXCL4 in Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms: A New Potential Prognostic Factor for Disease Progression
2025 V. Bellani, D. Cattaneo, V. Abbonante, C. Bucelli, S. Stella, B. Mora, A. Malara, U. Gianelli, A. Balduini, A. Iurlo
Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options
2025 A. Iurlo, D. Cattaneo, U. Gianelli, F. Passamonti
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera
2025 T. Barbui, A. Ghirardi, V. Empson, F. Fenili, G.G. Loscocco, A. Condorelli, A. Iurlo, D. Cattaneo, E. Rossi, V. De Stefano, P. Guglielmelli, C. Klade, H. Gisslinger, A. Rambaldi, J.M. Scandura, A.M. Vannucchi
The 2024 Three‐Strata Baseline Anemia Definition of the Revised IWG‐ELN Criteria Dissects Survival in Ruxolitinib‐Treated Myelofibrosis Patients
2025 M. Maffioli, B. Mora, A. Iurlo, E.M. Elli, M.C. Finazzi, M. Farina, E. Rumi, M. Caramella, M.C. Carraro, M. D'Adda, A. Molteni, E. Mimiola, F. Lunghi, A. Vismara, M. Ubezio, M.C. Di Chio, M. Anghilieri, D. Cattaneo, M.G. Della Porta, L. Bertù, M. Coscia, F. Passamonti
SETD2 loss of function is a recurrent event in advanced‐phase chronic myeloid leukemia and contributes to genomic instability
2025 M. Mancini, S. De Santis, C. Monaldi, F. Castagnetti, M. Iezza, A. Iurlo, D. Cattaneo, S. Galimberti, M. Cerrano, I. Capodanno, M. Bonifacio, M. Rossi, C. Agostinelli, M. Meggendorfer, T. Haferlach, M. Cavo, G. Gugliotta, S. Soverini
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
2024 O. Mulas, E. Abruzzese, L. Luciano, A. Iurlo, I. Attolico, F. Castagnetti, S. Galimberti, M. Bonifacio, M. Annunziata, A. Gozzini, E.M. Orlandi, F. Stagno, G. Binotto, P. Pregno, C. Fozza, M. Loi, M.M. Trawinska, F. De Gregorio, D. Cattaneo, F. Albano, M. Iezza, C. Baratè, L. Scaffidi, C. Elena, V. Giai, E. Scalzulli, M. Breccia, G. La Nasa, G. Caocci
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial
2024 B. Rocca, A. Tosetto, G. Petrucci, E. Rossi, S. Betti, D. Soldati, A. Iurlo, D. Cattaneo, C. Bucelli, A. Dragani, M. Di Ianni, P. Ranalli, F. Palandri, N. Vianelli, E. Beggiato, G. Lanzarone, M. Ruggeri, G. Carli, E.M. Elli, R. Renso, M.L. Randi, I. Bertozzi, G.G. Loscocco, A. Ricco, G. Specchia, A.M. Vannucchi, F. Rodeghiero, V. De Stefano, C. Patrono
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
2024 F. Palandri, G. Auteri, E. Abruzzese, G. Caocci, M. Bonifacio, F. Mendicino, R. Latagliata, A. Iurlo, F. Branzanti, B. Garibaldi, M.M. Trawinska, D. Cattaneo, M. Krampera, O. Mulas, E.A. Martino, M. Cavo, N. Vianelli, S. Impera, F. Efficace, F. Heidel, M. Breccia, E.M. Elli, G.A. Palumbo
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study
2024 F. Palandri, E.M. Elli, E. Morsia, G. Benevolo, M. Tiribelli, E. Beggiato, M. Bonifacio, M. Farina, B. Martino, G. Caocci, N. Pugliese, A. Tieghi, M. Crugnola, G. Binotto, F. Cavazzini, E. Abruzzese, A. Iurlo, A. Isidori, C. Bosi, V. Guglielmana, M. Venturi, A. Dedola, M. Loffredo, G. Fontana, A. Duminuco, A. Moioli, L. Tosoni, E. Scalzulli, D. Cattaneo, R.M. Lemoli, D. Cilloni, M. Bocchia, F. Pane, F.H. Heidel, N. Vianelli, M. Cavo, G.A. Palumbo, F. Branzanti, M. Breccia
Prognostic and Predictive Models in Myelofibrosis
2024 B. Mora, C. Bucelli, D. Cattaneo, V. Bellani, F. Versino, K. Barbullushi, N. Fracchiolla, A. Iurlo, F. Passamonti